Literature DB >> 30421345

Correcting QT for Heart Rate When Both are Affected by a Drug.

Georg Ferber1.   

Abstract

Mesh：

Year:  2019        PMID： 30421345     DOI： 10.1007/s40264-018-0749-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  10 in total

1.  Estimation of the QT/RR hysteresis lag.

Authors:  Esther Pueyo; Peter Smetana; Pablo Laguna; Marek Malik
Journal:  J Electrocardiol       Date:  2003       Impact factor: 1.438

Review 2.  Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects.

Authors:  Christine E Garnett; Hao Zhu; Marek Malik; Anthony A Fossa; Joanne Zhang; Fabio Badilini; Jianguo Li; Börje Darpö; Philip Sager; Ignacio Rodriguez
Journal:  Am Heart J       Date:  2012-05-04       Impact factor: 4.749

3.  Creation of a knowledge management system for QT analyses.

Authors:  Christoffer W Tornøe; Christine E Garnett; Yaning Wang; Jeffry Florian; Michael Li; Jogarao V Gobburu
Journal:  J Clin Pharmacol       Date:  2010-10-26       Impact factor: 3.126

4.  Bias and variance evaluation of QT interval correction methods.

Authors:  Yibin Wang; Guohua Pan; Alfred Balch
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

5.  Validation of QT Interval Correction Methods When a Drug Changes Heart Rate.

Authors:  Qianyu Dang; Joanne Zhang
Journal:  Ther Innov Regul Sci       Date:  2013-03       Impact factor: 1.778

6.  Electrical and mechanical restitution of the human heart at different rates of stimulation.

Authors:  M R Franz; J Schaefer; M Schöttler; W A Seed; M I Noble
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

7.  Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.

Authors:  Marek Malik; Christine Garnett; Katerina Hnatkova; Lars Johannesen; Jose Vicente; Norman Stockbridge
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-12       Impact factor: 2.745

8.  Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Authors:  Boaz Mendzelevski; Georg Ferber; Filip Janku; Bob T Li; Ryan J Sullivan; Dean Welsch; Wei Chi; Jeanne Jackson; Onglee Weng; Philip T Sager
Journal:  Cancer Chemother Pharmacol       Date:  2018-03-30       Impact factor: 3.333

9.  Implications of Individual QT/RR Profiles-Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes.

Authors:  Marek Malik; Christine Garnett; Katerina Hnatkova; Jose Vicente; Lars Johannesen; Norman Stockbridge
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

10.  Implications of Individual QT/RR Profiles-Part 1: Inaccuracies and Problems of Population-Specific QT/Heart Rate Corrections.

Authors:  Marek Malik; Christine Garnett; Katerina Hnatkova; Jose Vicente; Lars Johannesen; Norman Stockbridge
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.228
  10 in total
  1 in total

1.  Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects.

Authors:  Borje Darpo; Hongqi Xue; S Ken Tanaka; Evan Tzanis
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.